Humanigen Inc (HGENQ)

[Corundum]

Looks like KNSA may have a weak study. 573 participants in Phase 2/3, but the patients are split into six groups. Half are already ventilated, with a 3-way split between placebo and either 6 or 10 milligrams per kilogram of body weight. The other half are not yet on ventilators, but require supplemental oxygen.

So they may get an approval for vented patients (Lenz is intended for pre-vent, and if successful, there may be few vent patients left to serve!). For the non-vented, the study looks underpowered (size of study for statistical significance), and lower dosage (maybe half the HGEN dosage?), so it may not be competitive with HGEN.

Cross your fingers.